Investing.com — Moderna , Inc. (NASDAQ:MRNA) today confirmed that it has won a tender to supply its mRNA COVID-19 vaccine in the European Union (EU), Norway, and North Macedonia. The agreement, valid for up to four years, allows 17 countries to access Moderna’s vaccine.
Chantal Friebertshäuser, Senior Vice President, General Manager – Europe & Middle East, Moderna, stated that the agreement would enable Moderna to bolster national COVID-19 vaccination drives across the participating nations. She emphasized the importance of diverse supply sources and the availability of various vaccine formats like prefilled syringes to improve vaccination rates and campaign efficiency, ultimately reinforcing health security.
The agreement permits Moderna to supply its COVID-19 vaccine in various formats, including prefilled syringes. This format is favored by healthcare providers as it can reduce the risk of administration mistakes and save time, potentially enhancing the efficiency of vaccination campaigns.
In September 2024, the European Commission (EC) authorized the marketing of an updated version of Moderna’s COVID-19 mRNA vaccine Spikevax. This new formulation targets the SARS-CoV-2 variant JN.1 and is designed for active immunization to prevent COVID-19 in individuals aged six months and older.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
